Collplant Holdings (CLGN) has released an update.
CollPlant Biotechnologies has initiated pre-clinical trials of 200cc regenerative breast implants using a 3D printing collaboration with Stratasys, targeting a $3.0 billion market opportunity. Despite the innovative advances, the company reported a significant decrease in GAAP revenues for Q2 2024 compared to the previous year, as well as a net loss, attributed to a one-time milestone payment in 2023. CollPlant also highlighted its commitment to environmental and social governance in its inaugural sustainability report.
For further insights into CLGN stock, check out TipRanks’ Stock Analysis page.
